Anticonvulsants

PreclinicalSmall molecule

SSt. Petersburg State Pavlov Medical University

Anticonvulsants is one of 24 small molecule programs targeting Alcohol Withdrawal. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol WithdrawalActive, not recruiting

Alcohol WithdrawalPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Alcohol Withdrawal

#DrugCompanyPhaseTrials

Lioresal

Novartis

Approved

5 2

Depakote

Teva

Approved

1 3

Xyrem

Jazz Pharmaceuticals

Approved

1 4

Ativan

BBausch Health Americas, Inc.

Approved

7 5

Minipress

Pfizer

Approved

—6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

4 7

Ketalar

AAultman Health Foundation

Approved

2 8

Pitocin

RRetrophin

Approved

—9

Epsom Salt

FFresenius Kabi Oncology Ltd.

Keppra

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Withdrawal1 trial

Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome

Completed·SSt. Petersburg State Pavlov Medical University·N/A·NCT00241995

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anticonvulsants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticonvulsants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticonvulsants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Petersburg State Pavlov Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSt. Petersburg State Pavlov Medical University

Anticonvulsants

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Withdrawal1 trial

References

Drug Info

Quick Facts

Related News